The Treatment of Severe Aplastic Anemia: Outcomes of Bone Marrow Transplantation and Immunosuppressive Therapy in a Single Institution of Korea

Journal of Korean Medical Science

Volumn 18, Issue 3, 2003, Pages 365-371

  Kim, Inho ^a,b   Yoon, Sung Soo ^a   Park, Seonyang ^a   Kim, Byoung Kook ^a   Kim, Noe Kyeong ^a  

^a Seoul National University   (South Korea)

^b Inha University School of Medicine   (South Korea)

Author keywords

Anemia, Aplastic; Bone Marrow Transplantation; Immunosuppression; Korea

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BLEEDING; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE SEVERITY; EVALUATION; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROGNOSIS; RECURRENT DISEASE; SIBLING; SIDE EFFECT; SOUTH KOREA; STATISTICAL ANALYSIS; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; VEIN OCCLUSION;

EID: 0345802740     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2003.18.3.365     Document Type: Article

References (27)

1. Champlin RE, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med 1983; 308: 113-5.
2. Marmont AM, Bacigalupo A, Van Lint MT, Frassoni F, Risso M, Cerri R, Rossi E, Damasio EE, Santini G, Carella AM. Treatment of severe aplastic anemia with sequential immunosuppression. Exp Hematol 1983; 11: 856-65.
3. Gluckman E, Devergie A, Faille A, Barrett AJ, Bonneau M, Boiron M, Bernard J. Treatment of severe aplastic anemia with antilymphocyte globulin and androgens. Exp Hematol 1978; 6: 679-87.
4. Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP, Rappeport JM, Storb R. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 1976; 48: 63-70.
5. Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint MT, Congiu M, De Planque MM, Ernst P, McCann S, Ragavashar A, Frickhofen N, Wursch A, Marmont AM, Gordon-Smith EC. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA Working Party. Br J Haematol 1988; 70: 177-82.
6. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, Lemer KG, Glucksberg H, Buckner CD. Bone-marrow transplantation. N Engl J Med 1975; 292: 895-902.
7. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4: 42-93.
8. Jones RJ, Lee KS, Beschomer WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R. Venoocclusive disease of the liver following bone marrow transplantation Transplantation 1987; 44: 778-83.
9. Marsh JC, Hows JM, Bryett KA, Al-Hashimi S, Fairhead SM, Gordon-Smith EC. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood 1987; 70: 1046-52.
10. Doney K, Leisenring W, Storb R, Appelbaum FR. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Ann Intern Med 1997; 126: 107-15.
11. Storb R, Weiden PL, Deeg HJ, Graham TC, Atkinson K, Slichter SJ, Thomas ED. Rejection of marrow from DLA-identical canine littermates given transfusion before grafting: antigens involved are expressed on leukocytes and epithelial cells but not on platelets and red blood cells. Blood 1979; 54: 477-84
12. Storb R, Thomas ED, Buckner CD, Appelbaum FR, Clift RA, Deeg HJ, Doney K, Hansen JA, Prentice RL, Sanders JE, Stewart P, Sullivan KM, Witherspoon RP. Marrow transplantation for aplastic anemia. Semin Hematol 1984; 21: 27-35.
13. Storb R, Thomas ED, Buckner CD, Clift RA, Deeg HJ, Feter A, Goodell BW, Sale GE, Sanders JE, Singer J, Stewart P, Weiden PL. Marrow transplantation in thirty untransfused patients with severe aplastic anemia. Ann Intern Med 1980; 92: 30-6.
14. Champlin RE, Horowitz MM, vanBekkum DW, Camitta BM, Elfenbein GE, Gale RP, Gluckman E, Good RA, Rimm AA, Rozman C, Speck B, Bortin MM. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73: 606-13.
15. Bortin MM, Horowitz MM, Gale RP. Current status of bone marrow transplantation in humans: report from the International Bone Marrow Transplant Registry. Nat Immun Cell Growth Regul 1988; 7: 334-50.
16. Kim DJ, Kim CC, Kim BK, Kim DW, Lee JW, Jin JY, Han CW, Min WS, Park CW, Kim HK, Kim WI, Hahn JS, Hwang TJ, Park JW. Allogeneic bone marrow transplantation in Korea: 1983-92. Bone Marrow Transplant 1994; 13: 717-9.
17. Jin JY, Kim DW, Lee JW, Han CW, Min WS, Park CW, Kim CC, Kim DJ, Kim HK, Song HH. Immune suppression therapy in aplastic anemia: influencing factors on response and survival. Korean J Intern Med 1995; 10: 25-31.
18. Paquette RL, Tebyani N, Frane M, Ireland P, Ho WG, Chaplin RE, Nimer SD. Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood 1995; 85: 283-90.
19. Oriol R, Le Pendii J, Chun C. Influence of the original disease, rac, and center on the outcome of kidney transplantation. Transplantation 1982; 33: 22-6.
20. Santos GW. Critical issues in transplants in aplastic anemia. In: Gale RP, editor, Recent Advances in Bone Marrow Transplantation. New York: Alan R. Liss, 1983: 11-20.
21. Klingemann HG, Deegs HJ, Self S, Thomas ED, Storb R. Is the race a risk factor for allogeneic marrow transplantation? Bone Marrow Transplant 1986; 1: 87-94.
22. De Planque MM, Bacigalupo A, Wursch A, Hows JM, Devergie A, Frickhofen N, Brand A, Nissen C. Long-term follow-up of severe aplastic anemia patients treated with anti-thymocyte globulin. Br J Haematol 1989; 73: 121-6.
23. Young N, Griffith P, Brittain E, Elfenbein G, Gardner F, Huang A, Harmon D, Hewlett J, Fay J, Mangan K, Morrison F. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood 1988; 72: 1861-9.
24. Champlin RE, Ho WG, Feig SA, Winston DJ, Lenarsky C, Gale RP. Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Blood 1985; 66: 184-8.
25. Frickhofen N, Joachim PK, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F, Freund M, Meusers P, Salama A, Heimpel H. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 1991; 324: 1297-304.
26. Crump M, Larratt LM, Maki E, Curtis JE, Minden MD, Meharchand JM, Lipton JH, Messner HA. Treatment of adults with severe aplastic anemia: primary therapy with antithymocyte globulin (ATG) and rescue of ATG failure with bone marrow transplantation. Am J Med 1992; 92: 596-602.
27. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe aplastic anemia. Blood 1995; 85: 3058-65.